Image Name

Enterprise News

Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"

Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"

Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.

Time：2024-10-23 17:49

Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study

Jiangsu Vcare's Oral Treatment VC005 for Atopic Dermatitis enters Phase III Clinical Study

VC005 tablets, developed by Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare), is a new-generation highly selective JAK1 inhibitor. The oral treatment of moderate-to-severe atopic dermatitis has initiated a Phase III clinical trial. It is a multicenter, randomized, double-blind, placebo parallel-controlled Phase III clinical study, aiming to evaluate the efficacy and safety of VC005 tablets for adult patients with moderate-to-severe atopic dermatitis. The trial is led by the Institute of Dermatology, Chinese Academy of Medical Sciences.

Time：2024-10-22 17:33

Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA

Jiangsu Vcare's New-generation TRK Inhibitor VC004 Obtains IND Approval from the US FDA

On October 16, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (referred to as "Jiangsu Vcare")'s independently developed new-generation anti-resistant TRK inhibitor VC004 achieved a significant milestone progress, and the project officially obtained the Investigational New Drug (IND) permission from the US Food and Drug Administration (FDA). This fully demonstrates Jiangsu Vcare's excellent drug research and development capabilities and is a successful practice of the company's strategies based on original innovation, high-quality standards, and a global layout.

Time：2024-10-17 17:29

Jiangsu Vcare’s Next-Generation TRK Inhibitor VC004 IND Application was accepted by the US FDA

Jiangsu Vcare’s Next-Generation TRK Inhibitor VC004 IND Application was accepted by the US FDA

At the end of September 2024, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that the US FDA has officially accepted the Investigational New Drug (IND) application of its independently developed new-generation anti-resistant TRK inhibitor VC004. This milestone paves the way for the global commercialization strategy.

Time：2024-09-24 17:26

Jiangsu Vcare Pharmatech Co., Ltd. Selected as National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises

Jiangsu Vcare Pharmatech Co., Ltd. Selected as National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises

Recently, the Ministry of Industry and Information Technology (MIIT) announced the sixth batch of National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises, andJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was successfully selected. Thisnational-levelhonor fully demonstrates that under its "dual-core business model," Jiangsu Vcare's scientific research capabilities, independent innovation capacity, market leadership, and future development potential have received official high recognition.

Time：2024-09-09 17:47

Jiangsu Vcare Announces Successfully Unblinding of VC005 Topical Gel Clinical Phase I Data

Jiangsu Vcare Announces Successfully Unblinding of VC005 Topical Gel Clinical Phase I Data

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful unblinding of Phase I clinical data for its self-developed VC005 gel, a second-generation selective JAK1 inhibitor, in the topical treatment of mild-to-moderate atopic dermatitis (AD). The results demonstrated exceptional safety and significant efficacy.

Time：2024-08-16 17:23

Jiangsu Vcare's VC005 has Achieved Positive Topline Data in the Phase II Clinical Trial for the Oral Treatment of Atopic Dermatitis

Jiangsu Vcare's VC005 has Achieved Positive Topline Data in the Phase II Clinical Trial for the Oral Treatment of Atopic Dermatitis

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced positive topline data from its Phase II clinical trial of VC005 tablets, a second-generation selective JAK1 inhibitor, for the oral treatment of moderate-to-severe atopic dermatitis (AD).

Time：2024-08-14 17:40

Announcement on Company Name Change by Jiangsu Vcare Pharmatech Co., Ltd.

Announcement on Company Name Change by Jiangsu Vcare Pharmatech Co., Ltd.

July 12, 2024, Jiangsu Vcare Pharmatech Co., Ltd. (hereinafter referred to as "the Company") has completed the industrial and commercial registration for its name change and obtained the renewed Business License issued by the Administrative Approval Bureau of Nanjing Jiangbei New Area.

Time：2024-07-19 17:44

< 1...456...11 >
Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Company Address:

No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

Subsidiary NJVcare Website：

en.njvcare.com

Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Scan to see

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.

SEO

图片名称

苏公网安备32011202001742号

Powerby：www.300.cn nanjing.300.cn